Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report released on Thursday, MarketBeat reports.

Several other research firms have also recently commented on MIST. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, July 14th. Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price objective on the stock. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Wells Fargo & Company dropped their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $6.40.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.20 on Thursday. Milestone Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $3.06. The company has a market capitalization of $149.40 million, a price-to-earnings ratio of -1.74 and a beta of 0.98. The firm has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $1.44. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.82 million. On average, equities research analysts anticipate that Milestone Pharmaceuticals will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MIST. Strategic Family Wealth Counselors L.L.C. purchased a new stake in Milestone Pharmaceuticals during the fourth quarter worth $25,000. Eaton Financial Holdings Company LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth about $26,000. HighTower Advisors LLC grew its stake in Milestone Pharmaceuticals by 100.0% in the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after acquiring an additional 10,000 shares during the last quarter. Welch & Forbes LLC purchased a new position in shares of Milestone Pharmaceuticals during the 1st quarter worth approximately $30,000. Finally, Bank of America Corp DE increased its position in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after buying an additional 16,044 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.